Howe & Rusling’s Bellicum Pharmaceuticals, Inc. BLCM Stock Holding History

Howe & Rusling’s Portfolio BLCM Stock Details BLCM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2016 Q3	–	Sell	-3	Closed	–	–	1147
2016 Q2	$0	Hold	3	–	–	﹤0.01%	1070
2016 Q1	$0	Hold	3	–	–	﹤0.01%	1072
2015 Q4	$1K	Hold	3	–	–	﹤0.01%	953
2015 Q3	$0	Hold	3	–	–	﹤0.01%	1087
2015 Q2	$1K	Buy	+3	New	+$735	﹤0.01%	994

Other funds holding BLCM

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return

Howe & Rusling's BLCM Position: Q3 2016 in Review

Howe & Rusling sold out of Bellicum Pharmaceuticals, Inc. (BLCM) in Q3 2016, closing a stake of 3 shares.

Howe & Rusling first reported a position in BLCM in Q2 2015 and held it in 5 quarters. The position peaked at $1K in Q4 2015. 70 funds tracked by Wall St. Rank hold BLCM as of Q3 2016.

Howe & Rusling reported no remaining Bellicum Pharmaceuticals, Inc. position as of Q3 2016 after selling out during the quarter.
Howe & Rusling sold 3 Bellicum Pharmaceuticals, Inc. shares in Q3 2016.
Howe & Rusling first reported a position in Bellicum Pharmaceuticals, Inc. in Q2 2015 and held it in 5 quarters.
Howe & Rusling's Bellicum Pharmaceuticals, Inc. position peaked at $1K in Q4 2015.
70 funds tracked by Wall St. Rank held Bellicum Pharmaceuticals, Inc. as of Q3 2016.

Based on Howe & Rusling's 13F filing for Q3 2016, filed 17 Oct 2016.